U.s. patent office issues new patent to renovorx for novel trans-arterial micro-profusion (tamp™) therapy platform

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared drug-delivery device, today announced that it has received an issue notification from the u.s. patent and trademark office (uspto) indicating that u.s. patent no. 12,290,564, becomes effective today, may 6, 2025. this patent, titled “methods for treating tumors,” expand.
RNXT Ratings Summary
RNXT Quant Ranking